Publications 2015-2019

Langley PC. The status of modeled claims (Editorial). J Med Econ. 2015;18(12):991-2

Langley PC. Validation of modeled pharmacoeconomic claims in formulary submissions, J Med Econ. 2015;18(12):993-99

Langley PC. Imaginary Worlds: Reproducibility and Modeled Claims in Precision Medicine. J Precision Medicine. 2016; March/April:17-22

Langley PC. Na domhain shamhlaíochta: formulary submission guidelines in Ireland and the standards of normal science. Curr Med Res Opin. 2016;32(5):DOI:10.1080/03007995.2016.1190699

Langley PC.  Imaginary worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 2015. InovPharm . 2016;7(2): No. 9.

Langley PC. Nullius in verba: the University of Minnesota Social and Administrative Pharmacy program proposed Guidelines for Formulary Evaluations.   InovPharm. 2016;7(2): No. 10.

Langley PC. Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions, InovPharm. 2016;7(2): No.11

Langley PC.  Sunlit uplands: the genius of the NICE reference case. InovPharm. 2016;7(2): No.12.

Langley PC. He Ao Pohewa: The PHARMAC Prescription for Pharmacoeconomic Analysis in New Zealand and the standards of normal science. InovPharm. 2016;7(2): No. 13.

Langley PC.  Great expectations: Cost-utility models as decision criteria. InovPharm . 2016;7(2): No.14.

Langley PC.  Supporting formulary decisions: The discovery of new facts or constructed evidence?  InovPharm. 2016;7(2): No.15.

Langley PC, Rhee TG.  Imaginary worlds: A systematic review of the status of modeled cost-effectiveness claims published in the Journal of Medical Economics from January 2015 to December 2015.  InovPharm . 2016;7(2): No. 16.

Langley PC, Rhee TG. Imaginary Worlds: The status of simulation modeling in claims for cost-effectiveness in diabetes mellitus.  InovPharm . 2016;7(2): No. 17.

Langley PC, Rhee TG.Imaginary worlds: The status of modeled economic evaluation claims published in Value in Health January 2015 to December 2015. InovPharm . 2016;7(2): No. 18.

Langley PC. Imaginary Worlds: The European Network for Health Technology Assessment (EUnetHTA) Recommendations for Health Economic Evaluations. InovPharm. 2016;7(3): No. 3

Langley PC. Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure. InovPharm. 2016;7(3): No. 6

Langley PC, Rhee TG. Imaginary Worlds: The Status of Modeled Quality Adjusted Life Year Claims for New Oral Anticoagulants in Atrial Fibrillation Published Between January 2012 and February 2016. InovPharm. 2016;7(3): No.7

Langley PC. Next Generation Sequencing Claims in Precision Medicine: Questions a Formulary Committee Should Ask. InovPharm. 2016;7(4): No. 11

Langley PC. Creative Destruction: Next Generation Sequencing in Drug Development, Formulary Evaluations and Pricing. InovPharm. 2016;7(4): No. 13

Langley PC. Nullius in Verba: Version 2.0 of the University of Minnesota, School of Social and Administrative Pharmacy Program, Proposed Guidelines for Formulary Evaluation. InovPharm. 2016;7(4): No 16

Langley PC. Establishing the promise of next generation sequencing: The Minnesota Guidelines. J Precision Med. Nov/Dec 2016

Langley PC. Validating Imaginary Worlds? The AdViSHE Assessment Tool. InovPharm. 2017;8(1): No.3

Langley PC. Denkbeeldige Wereld: The New Dutch Guidelines for Economic Evaluations in Healthcare. InovPharm. 2017;8(1): No. 4

Langley PC. Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC). InovPharm. 2017;8(1): No. 5

Langley PC. HAS Should Not Be NICE: Rejecting Imaginary Worlds in the French Technology Assessment Guidelines. InovPharm. 2017;8(1): No. 8

Langley PC. Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report of the Institute for Clinical and Economic Review (ICER). InovPharm. 2017;8(1): No. 12

Langley PC. Imaginary Worlds and Efficiency Frontiers: Should We Abandon the IQWiG Health Technology Assessment Model? InovPharm. 2017;8(1): No. 13

Langley PC. Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An Overview of Commentaries in Innovations in Pharmacy from July 2016 to February 2017. InovPharm. 2017;8(1): No. 22

Langley PC. True North: Building Imaginary Worlds with the Revised Canadian (CADTH) Guidelines for Health Technology Assessment. InovPharm. 2017;8(2): No. 9.

Langley PC. Imaginary Worlds and the Institute for Clinical and Economic Review (ICER) Evidence Report: Targeted Immune Modulators for Rheumatoid Arthritis. InovPharm. 2017;8(2): No. 10.

Langley PC. Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors. InovPharm. 2017;8(2): No. 11

Langley PC, Rhee T. The Imaginary Worlds of ISPOR: Modeled Cost-Effectiveness Claims Published in Value in Health from January 2016 to December 2016. InovPharm. 2017;8(2): No. 14

Langley PC. Potentially Actionable Targets: Evidence Standards for Credible Next Generation Sequencing Technology Assessment Claims. InovPharm. 2017;8(3): No. 9

Langley PC, Rhee TG. More Imaginary Worlds: A Systematic Review of the Status of Modeled Cost-Effectiveness Claims Published in the Journal of Medical Economics from January 2016 to December 2016. InovPharm. 2017;8(3): No. 13

Langley PC. Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER Value Assessment Update. InovPharm. 2017;8(4): No 7

Langley PC. Transparency, Imaginary Worlds and ICER Value Assessments. InovPharm.  2017;8(4): No 11

Langley PC. Another Imaginary World: The ICER Claims for the Long-Term Cost-Effectiveness and Pricing of Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors in Tardive Dyskinesia. InovPharm. 2017;8(4): No 12

Langley PC. Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds. InovPharm. 2018;9(2): No. 10

Langley PC. CVS Health and the imaginary worlds of the Institute for Clinical and Economic Review (ICER). InovPharm. 2018; 9(4):No. 4

Langley PC. Another Rush to Judgement: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy. InovPharm. 2019;10(3):No. 11

Langley PC. The Imaginary Worlds of Cure Proportion Modeling: Survivorship and Reference Case Pricing of Transformative Therapies. InovPharm. 2019;10(3): No. 17

Langley PC. ICER, ISPOR and QALYs: A Tale of Imaginary Worlds, InovPharm. 2019:10(4): No. 10

Langley PC. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies. InovPharm.2019;10(4); No. 22